Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com

StockNews.com upgraded shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) from a buy rating to a strong-buy rating in a report released on Thursday.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $10.00.

Aurinia Pharmaceuticals Trading Down 3.2 %

Shares of AUPH stock opened at $8.07 on Thursday. Aurinia Pharmaceuticals has a 12 month low of $4.71 and a 12 month high of $10.67. The company has a market cap of $1.16 billion, a PE ratio of -53.80 and a beta of 1.24. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average is $8.74 and its two-hundred day moving average is $7.23.

Insiders Place Their Bets

In other Aurinia Pharmaceuticals news, Director Jeffrey Allen Bailey sold 4,557 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the sale, the director now directly owns 13,356 shares in the company, valued at $112,591.08. This trade represents a 25.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. State Street Corp increased its stake in Aurinia Pharmaceuticals by 2.3% during the third quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock valued at $21,587,000 after acquiring an additional 64,949 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Aurinia Pharmaceuticals by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock worth $5,454,000 after acquiring an additional 89,940 shares during the period. Segall Bryant & Hamill LLC grew its holdings in shares of Aurinia Pharmaceuticals by 1.6% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock worth $4,125,000 after purchasing an additional 9,031 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Aurinia Pharmaceuticals by 4,307.9% during the third quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company’s stock valued at $4,015,000 after purchasing an additional 535,301 shares during the period. Finally, Bank of New York Mellon Corp raised its stake in shares of Aurinia Pharmaceuticals by 18.8% in the second quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company’s stock valued at $2,791,000 after purchasing an additional 77,510 shares in the last quarter. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.